KBP 5660Alternative Names: 5660; KBP-5660
Latest Information Update: 21 Sep 2016
At a glance
- Originator XuanZhu Pharma
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cardiovascular disorders
Most Recent Events
- 11 Apr 2016 Phase-I clinical trials in Cardiovascular disorders in China (unspecified route) (XuanZhu Pharma pipeline, April 2016)